T1	Participants 349 386	6797 patients with ejection fractions
T2	Participants 647 774	Patients with heart failure entered the treatment trial (n = 2569) and those without heart failure entered the prevention trial
T3	Participants 942 1084	158 placebo vs 127 enalapril, p < 0.02; prevention trial: 204 vs 161 p < 0.01) or unstable angina (240 vs 187 p < 0.001; 355 vs 312, p < 0.05)
T4	Participants 1107 1133	362 placebo group patients
T5	Participants 1107 1160	362 placebo group patients with myocardial infarction
T6	Participants 1250 1276	595 placebo group patients
